Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments, and Licenses - Summary of Investments (Details)

v2.4.0.8
Acquisitions, Investments, and Licenses - Summary of Investments (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
Jun. 30, 2014
Dec. 31, 2013
Investment [Line Items]    
Investment, available for sale $ 4,745 $ 4,301
Plus unrealized gains on investments, options and warrants, net 8,827  
Less accumulated losses in investees (18,696)  
Investments, net 33,428 [1] 30,653 [1]
Neovasc
   
Investment [Line Items]    
Ownership at June 30, 2014 6.00%  
Investment, equity method 3,798  
Underlying equity in net assets 1,454  
Senesco
   
Investment [Line Items]    
Ownership at June 30, 2014 4.00%  
Investment, equity method 750  
Investment, available for sale 228  
Underlying equity in net assets 366  
RXi
   
Investment [Line Items]    
Ownership at June 30, 2014 15.00%  
Investment, equity method 15,000  
Underlying equity in net assets 1,918  
Pharmsynthez
   
Investment [Line Items]    
Ownership at June 30, 2014 17.00%  
Investment, equity method 11,300  
Underlying equity in net assets 6,405  
Zebra
   
Investment [Line Items]    
Ownership at June 30, 2014 19.00%  
Investment, equity method 2,000  
Underlying equity in net assets 840  
Cocrystal/BZNE
   
Investment [Line Items]    
Ownership at June 30, 2014 16.00%  
Investment, equity method 5,476  
Underlying equity in net assets 993  
Neovasc Options
   
Investment [Line Items]    
Investment, available for sale 925  
Closing share price at June 30, 2014 for investments available for sale $ 6.25  
ChromaDex
   
Investment [Line Items]    
Ownership at June 30, 2014 1.00%  
Investment, available for sale 1,320  
Closing share price at June 30, 2014 for investments available for sale $ 1.30  
ARNO
   
Investment [Line Items]    
Ownership at June 30, 2014 5.00%  
Investment, available for sale 2,000  
Closing share price at June 30, 2014 for investments available for sale $ 1.78  
Cocrystal Warrants
   
Investment [Line Items]    
Investment, available for sale $ 500  
[1] As of June 30, 2014 and December 31, 2013, total assets include $7.7 million and $6.7 million, respectively, and total liabilities include $13.5 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.